Ignite Creation Date:
2024-05-05 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00047736
Status:
COMPLETED
Last Update Posted:
2013-06-21
First Post:
2002-10-16
Brief Title:
A Study With Tarceva and Chemotherapy vs Chemotherapy Alone in Patients With Advanced Lung Cancer
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase III Randomized Double Blind Multicenter Trial of Tarceva Erlotinib Plus Chemotherapy Carboplatin and Paclitaxel Versus Chemotherapy Alone in Patients With Advanced Stage IIIb or IV Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if Tarceva plus standard chemotherapy is more effective than standard chemotherapy alone in the treatment of lung cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None